186 related articles for article (PubMed ID: 34837065)
1. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411
Singleton DC; Mowday AM; Guise CP; Syddall SP; Bai SY; Li D; Ashoorzadeh A; Smaill JB; Wilson WR; Patterson AV
Cancer Gene Ther; 2022 Jul; 29(7):1021-1032. PubMed ID: 34837065
[TBL] [Abstract][Full Text] [Related]
2. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
[TBL] [Abstract][Full Text] [Related]
3. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R
Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
5. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
[TBL] [Abstract][Full Text] [Related]
6. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
[TBL] [Abstract][Full Text] [Related]
9. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Weedon SJ; Green NK; McNeish IA; Gilligan MG; Mautner V; Wrighton CJ; Mountain A; Young LS; Kerr DJ; Searle PF
Int J Cancer; 2000 Jun; 86(6):848-54. PubMed ID: 10842200
[TBL] [Abstract][Full Text] [Related]
10. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
11. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
12. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
13. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
14. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
16. Repurposing
Ruiz de Garibay G; García de Jalón E; Stigen E; Lund KB; Popa M; Davidson B; Safont MM; Rygh CB; Espedal H; Barrett TM; Haug BE; McCormack E
Theranostics; 2021; 11(12):6044-6057. PubMed ID: 33897898
[TBL] [Abstract][Full Text] [Related]
17. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
Bridgewater JA; Springer CJ; Knox RJ; Minton NP; Michael NP; Collins MK
Eur J Cancer; 1995 Dec; 31A(13-14):2362-70. PubMed ID: 8652270
[TBL] [Abstract][Full Text] [Related]
18. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
Guise CP; Grove JI; Hyde EI; Searle PF
Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
20. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo.
Theys J; Pennington O; Dubois L; Anlezark G; Vaughan T; Mengesha A; Landuyt W; Anné J; Burke PJ; Dûrre P; Wouters BG; Minton NP; Lambin P
Br J Cancer; 2006 Nov; 95(9):1212-9. PubMed ID: 17024128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
